This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
extracellular vesicles | 578 |
summary conclusion | 561 |
study design | 534 |
blood donors | 497 |
case studies | 483 |
background case | 481 |
summary conclusions | 468 |
whole blood | 435 |
design method | 387 |
results finding | 375 |
red blood | 371 |
nucleic acid | 319 |
blood group | 316 |
blood bank | 304 |
flow cytometry | 273 |
blood transfusion | 270 |
electron microscopy | 243 |
blood cells | 243 |
blood donation | 241 |
red cell | 226 |
blood products | 211 |
blood components | 206 |
bone marrow | 203 |
blood cell | 196 |
positive samples | 189 |
mg kg | 181 |
performed using | 179 |
clinical samples | 171 |
stem cell | 171 |
mg dl | 168 |
blood donor | 158 |
cell lines | 158 |
significantly higher | 157 |
public health | 157 |
chain reaction | 152 |
sample preparation | 150 |
respiratory tract | 147 |
derived evs | 147 |
blood samples | 146 |
results findings | 144 |
polymerase chain | 144 |
blood center | 142 |
western blot | 142 |
nanoparticle tracking | 142 |
mass spectrometry | 141 |
transfusion reactions | 139 |
design methods | 138 |
tracking analysis | 138 |
nucleic acids | 136 |
clinical signs | 133 |
infectious diseases | 131 |
transfusion medicine | 130 |
ng ml | 129 |
see chapter | 128 |
gene expression | 125 |
statistically significant | 121 |
time pcr | 120 |
significant differences | 116 |
significant difference | 114 |
lateral flow | 114 |
red cells | 114 |
influenza virus | 112 |
blood product | 112 |
stem cells | 112 |
mg ml | 111 |
transmission electron | 108 |
isothermal amplification | 107 |
quality control | 105 |
room temperature | 103 |
transfusion service | 103 |
viral load | 102 |
cancer cells | 101 |
blood donations | 101 |
samples collected | 101 |
platelet count | 101 |
united states | 100 |
rbc units | 100 |
control group | 99 |
risk factors | 99 |
determine whether | 97 |
present study | 96 |
total number | 96 |
platelet concentrates | 94 |
peripheral blood | 93 |
blood supply | 93 |
first time | 92 |
adverse events | 92 |
sample collection | 92 |
breast cancer | 91 |
acute respiratory | 90 |
nanopore sequencing | 88 |
histologic study | 88 |
generation sequencing | 85 |
plasma samples | 85 |
doc id | 85 |
cord uid | 85 |
author funder | 83 |
spinal cord | 83 |
fecal samples | 83 |
granted medrxiv | 83 |
extracellular vesicle | 81 |
least one | 81 |
usa introduction | 81 |
blood services | 81 |
clinically significant | 80 |
prostate cancer | 80 |
associated conditions | 79 |
possible associated | 78 |
commercially available | 78 |
exclusion chromatography | 78 |
scanning electron | 77 |
pregnant women | 76 |
see also | 76 |
cell culture | 75 |
medical center | 75 |
cell types | 75 |
specimen preparation | 75 |
cell line | 74 |
derived exosomes | 74 |
may also | 73 |
serum samples | 73 |
genomic dna | 73 |
iu ml | 72 |
significantly lower | 72 |
blood banks | 70 |
significantly different | 70 |
reverse transcription | 70 |
blood centers | 70 |
respiratory syndrome | 70 |
derived extracellular | 69 |
upper respiratory | 69 |
copyright holder | 69 |
body weight | 68 |
escherichia coli | 68 |
expected findings | 68 |
recipient cells | 68 |
sickle cell | 68 |
two different | 67 |
air samples | 67 |
tissue samples | 67 |
two groups | 66 |
viral rna | 66 |
version posted | 66 |
healthy dogs | 66 |
deep sequencing | 65 |
western blotting | 65 |
red cross | 65 |
cancer cell | 65 |
related terms | 64 |
antibody screen | 64 |
amino acid | 64 |
results suggest | 63 |
commonly used | 63 |
differentially expressed | 63 |
size exclusion | 63 |
blood collection | 63 |
mesenchymal stem | 62 |
positive results | 62 |
sample size | 62 |
monte carlo | 62 |
two samples | 62 |
antibody screening | 62 |
world health | 61 |
massive transfusion | 61 |
endothelial cells | 61 |
mean age | 61 |
blood pressure | 61 |
rhce ce | 61 |
analyzed using | 61 |
widely used | 60 |
health organization | 60 |
rbc transfusion | 60 |
made available | 60 |
library preparation | 60 |
blood component | 60 |
external examination | 59 |
sanger sequencing | 59 |
statistical analysis | 59 |
illumina miseq | 59 |
faecal samples | 59 |
diagnostic tests | 59 |
patient samples | 59 |
mediated isothermal | 59 |
antigen expression | 59 |
epithelial cells | 58 |
blood service | 58 |
adverse reactions | 58 |
health care | 58 |
within hours | 58 |
transfusion reaction | 58 |
severe acute | 57 |
ev isolation | 57 |
iron deficiency | 57 |
pcr amplification | 57 |
submit samples | 57 |
clinical practice | 57 |
size distribution | 57 |
false positive | 56 |
national blood | 56 |
transfusion services | 56 |
flow strip | 56 |
negative results | 56 |
immune response | 56 |
hematopoietic stem | 56 |
test results | 56 |
small rna | 55 |
rna sequencing | 55 |
cell disease | 55 |
blood safety | 55 |
age group | 55 |
previous studies | 55 |
study period | 55 |
peer review | 54 |
next generation | 54 |
statistical significance | 54 |
swab samples | 54 |
one sample | 54 |
samples tested | 54 |
blood type | 54 |
acid amplification | 54 |
hemolytic transfusion | 53 |
infectious disease | 53 |
rhd gene | 53 |
respiratory viruses | 53 |
rna extraction | 53 |
rna viruses | 53 |
density gradient | 53 |
abstract withdrawn | 53 |
culture media | 52 |
large number | 52 |
per sample | 52 |
exposed controls | 52 |
blood volume | 52 |
rapid detection | 52 |
total rna | 52 |
pathogen reduction | 52 |
apheresis platelets | 51 |
ferritin levels | 51 |
electron beam | 51 |
negative samples | 51 |
respiratory disease | 51 |
dna sequencing | 51 |
electron microscope | 51 |
ms ms | 51 |
pg ml | 51 |
dna extraction | 51 |
international license | 51 |
standard deviation | 51 |
time donors | 50 |
risk factor | 50 |
viral loads | 50 |
blood loss | 50 |
cancer patients | 50 |
previously described | 50 |
significantly increased | 50 |
clinically relevant | 50 |
hand column | 49 |
medical records | 49 |
cd cells | 49 |
genome sequencing | 49 |
group system | 49 |
viral contigs | 49 |
samples using | 49 |
measured using | 49 |
human plasma | 49 |
heart failure | 48 |
patient blood | 48 |
age groups | 48 |
virus infection | 48 |
blood sample | 48 |
results indicate | 48 |
immune system | 48 |
control samples | 48 |
significantly reduced | 48 |
mental health | 48 |
three different | 48 |
trima accel | 48 |
bacterial contamination | 47 |
data analysis | 47 |
acute samples | 47 |
donor selection | 47 |
surface markers | 47 |
small extracellular | 47 |
blood management | 47 |
female donors | 47 |
ct values | 47 |
differential ultracentrifugation | 47 |
novel coronavirus | 47 |
respiratory samples | 47 |
nervous system | 47 |
negative control | 47 |
important role | 47 |
center background | 46 |
informed consent | 46 |
systematic review | 46 |
sequencing data | 46 |
abo rh | 46 |
molecular diagnostics | 46 |
cfu ml | 46 |
water supply | 45 |
liquid biopsy | 45 |
retrospective study | 45 |
tested using | 45 |
pig farmers | 45 |
analysis revealed | 45 |
drug resistance | 45 |
conditioned media | 45 |
study aimed | 45 |
plasma exchange | 45 |
copies ml | 44 |
high throughput | 44 |
lymph nodes | 44 |
urine samples | 44 |
procedures depend | 44 |
urinary bladder | 44 |
submit sample | 44 |
heart disease | 44 |
viral pathogens | 44 |
evs derived | 44 |
ev markers | 44 |
isolated evs | 44 |
turnaround time | 44 |
cerebrospinal fluid | 44 |
results obtained | 44 |
high risk | 44 |
growth factor | 44 |
multiplex pcr | 43 |
patient care | 43 |
median age | 43 |
monoclonal antibody | 43 |
type i | 43 |
years old | 43 |
based methods | 43 |
clinical specimens | 43 |
ev cargo | 43 |
may occur | 43 |
platelet counts | 43 |
intercellular communication | 43 |
significant increase | 43 |
real time | 43 |
viral reads | 43 |
see table | 42 |
medrxiv preprint | 42 |
terumo bct | 42 |
asian dust | 42 |
isolation methods | 42 |
sequence data | 42 |
cell surface | 42 |
main hydrated | 42 |
immunodeficiency virus | 42 |
hemolytic anemia | 42 |
per year | 42 |
time rt | 41 |
isolated using | 41 |
antiglobulin test | 41 |
patients undergoing | 41 |
metagenomic sequencing | 41 |
data suggest | 41 |
zika virus | 41 |
ev release | 41 |
grossly identified | 41 |
repeat donors | 41 |
lower respiratory | 41 |
pool size | 41 |
healthy controls | 41 |
male donors | 41 |
whole genome | 41 |
intensive care | 41 |
tumour cells | 41 |
platelet function | 41 |
frozen plasma | 41 |
anomaly detection | 41 |
may provide | 40 |
medical record | 40 |
may lead | 40 |
positive sample | 40 |
significantly decreased | 40 |
acid testing | 40 |
reference laboratory | 40 |
results showed | 40 |
university hospital | 40 |
thermo fisher | 40 |
tract infections | 40 |
high sensitivity | 40 |
assessed using | 40 |
identified abnormalities | 40 |
logistic regression | 40 |
wide range | 40 |
blood transfusions | 39 |
biological samples | 39 |
current study | 39 |
bact alert | 39 |
analysis showed | 39 |
blood groups | 39 |
waterborne illness | 39 |
evs isolated | 39 |
plasma units | 39 |
flow cytometric | 39 |
fisher scientific | 39 |
heart rate | 39 |
adverse effects | 39 |
wound healing | 39 |
different types | 39 |
pcr assay | 39 |
diabetes mellitus | 39 |
liver disease | 39 |
cord blood | 39 |
lymph node | 39 |
donor samples | 38 |
reverse transcriptase | 38 |
negative controls | 38 |
treated cells | 38 |
tested positive | 38 |
conditioned medium | 38 |
first step | 38 |
transfusion practice | 38 |
previously reported | 38 |
platelet transfusion | 38 |
hydrated hcqs | 38 |
drinking water | 38 |
antibody identification | 38 |
liquid chromatography | 38 |
year old | 38 |
clinical trials | 38 |
clinical trial | 38 |
future studies | 38 |
urinary tract | 38 |
differential centrifugation | 37 |
evaluated using | 37 |
pilot study | 37 |
may cause | 37 |
determined using | 37 |
respiratory syncytial | 37 |
rhd genotyping | 37 |
platelet aggregation | 37 |
magnetic beads | 37 |
protein content | 37 |
evs released | 37 |
blood units | 37 |
machine learning | 37 |
specific primers | 37 |
even though | 37 |
ex vivo | 37 |
pcr assays | 37 |
high prevalence | 37 |
healthy donors | 37 |
faecal virome | 37 |
lung cancer | 37 |
proteomic analysis | 37 |
platelet units | 36 |
test result | 36 |
cross section | 36 |
pcr products | 36 |
body mass | 36 |
stool samples | 36 |
septal defect | 36 |
case report | 36 |
ml kg | 36 |
results show | 36 |
dna samples | 36 |
patient safety | 36 |
highly sensitive | 36 |
human immunodeficiency | 36 |
scd patients | 36 |
single nucleotide | 36 |
analysis using | 36 |
diagnostic test | 36 |
month period | 35 |
fully automated | 35 |
may result | 35 |
diagnostic testing | 35 |
increased risk | 35 |
based detection | 35 |
contrast material | 35 |
urine sample | 35 |
pig buildings | 35 |
rhd negative | 35 |
relative abundance | 35 |
cell transplantation | 35 |
therapeutic plasma | 35 |
fresh frozen | 35 |
analysed using | 35 |
diagnostic tools | 35 |
expression levels | 35 |
water quality | 35 |
renal failure | 35 |
voluntary blood | 34 |
using two | 34 |
cell proliferation | 34 |
group antigens | 34 |
white blood | 34 |
farmworker families | 34 |
platelet products | 34 |
transfusion safety | 34 |
may help | 34 |
molecular testing | 34 |
also performed | 34 |
pathogen inactivation | 34 |
monoclonal antibodies | 34 |
cd cd | 34 |
safe blood | 34 |
total protein | 34 |
sample pooling | 34 |
ev subpopulations | 34 |
hemolytic disease | 34 |
abo blood | 34 |
bacterial culture | 34 |
syncytial virus | 34 |
side effects | 34 |
growth factors | 34 |
sample processing | 34 |
protein expression | 34 |
plasma evs | 34 |
target enrichment | 34 |
reference genome | 33 |
oxidative stress | 33 |
kidney disease | 33 |
one year | 33 |
recent years | 33 |
additive solution | 33 |
fold increase | 33 |
pooled samples | 33 |
hb levels | 33 |
also found | 33 |
iron supplementation | 33 |
infection control | 33 |
without fip | 33 |
genome sequence | 33 |
per ml | 33 |
procedures described | 33 |
linear regression | 33 |
veterinary medicine | 33 |
particle size | 33 |
viral infections | 33 |
emerging infectious | 33 |
body condition | 33 |
lg ml | 32 |
high level | 32 |
retrospective analysis | 32 |
molecular diagnostic | 32 |
time points | 32 |
patients received | 32 |
contigs singletons | 32 |
complete genome | 32 |
randomly selected | 32 |
capillary electrophoresis | 32 |
small evs | 32 |
information system | 32 |
one patient | 32 |
etiologic agent | 32 |
preliminary data | 32 |
closely related | 32 |
prospective study | 32 |
new york | 32 |
sequencing reads | 32 |
hours post | 32 |
storage period | 32 |
data show | 32 |
among blood | 32 |
odds ratio | 32 |
patients receiving | 32 |
surface area | 31 |
dna amplification | 31 |
serum albumin | 31 |
cell communication | 31 |
clinical data | 31 |
ct value | 31 |
individual samples | 31 |
consensus sequences | 31 |
pediatric patients | 31 |
blood vessels | 31 |
target cells | 31 |
gold standard | 31 |
viral sequences | 31 |
data collected | 31 |
three samples | 31 |
gastrointestinal tract | 31 |
cell units | 31 |
molecular detection | 31 |
resistance genes | 31 |
protein cargo | 31 |
using flow | 31 |
time point | 31 |
time series | 31 |
ill persons | 30 |
bronchoalveolar lavage | 30 |
buffy coat | 30 |
low hb | 30 |
cohort study | 30 |
study population | 30 |
regression analysis | 30 |
positive donations | 30 |
virus detection | 30 |
illumina sequencing | 30 |
nasopharyngeal swabs | 30 |
viral detection | 30 |
staphylococcus aureus | 30 |
genome sequences | 30 |
also tested | 30 |
regional blood | 30 |
transfusion protocol | 30 |
clinical symptoms | 30 |
calculated using | 30 |
relatively high | 30 |
social media | 30 |
apheresis platelet | 30 |
transfused patients | 30 |
left ventricular | 30 |
plasma membrane | 30 |
infectious agents | 30 |
viral families | 30 |
umbilical cord | 29 |
small number | 29 |
central nervous | 29 |
vitro quality | 29 |
virus reads | 29 |
transfusion vol | 29 |
reads mapping | 29 |
last years | 29 |
donor screening | 29 |
shelf life | 29 |
dna barcoding | 29 |
randomized controlled | 29 |
ev production | 29 |
within days | 29 |
stromal cells | 29 |
recent studies | 29 |
toxicologic study | 29 |
tumour microenvironment | 29 |
viral genomes | 29 |
fully integrated | 29 |
mouse model | 29 |
transport medium | 29 |
ebola virus | 29 |
american red | 29 |
surface marker | 29 |
positive control | 29 |
also used | 29 |
antimicrobial resistance | 29 |
family members | 29 |
tract infection | 29 |
human genome | 29 |
reference sequence | 29 |
high frequency | 29 |
tandem mass | 29 |
early detection | 28 |
donate blood | 28 |
supplement iv | 28 |
body fluids | 28 |
nasopharyngeal swab | 28 |
cd expression | 28 |
inclusion criteria | 28 |
physical examination | 28 |
scanning vol | 28 |
diagnostic sensitivity | 28 |
per month | 28 |
packed red | 28 |
control dogs | 28 |
high quality | 28 |
transmitted infections | 28 |
low viral | 28 |
autologous blood | 28 |
false negative | 28 |
ethics committee | 28 |
general population | 28 |
viral infection | 28 |
naturally occurring | 28 |
type ii | 28 |
optical reader | 28 |
high titer | 28 |
acid extraction | 28 |
tube method | 28 |
respiratory pathogens | 28 |
false positives | 28 |
three groups | 28 |
donor population | 28 |
new zealand | 28 |
culture medium | 28 |
samples taken | 28 |
high levels | 28 |
bacterial species | 28 |
rbc transfusions | 28 |
time period | 28 |
year period | 28 |
quality assurance | 27 |
transfusion transmitted | 27 |
electronic medical | 27 |
mitral valve | 27 |
smooth muscle | 27 |
host cells | 27 |
rare donor | 27 |
weak positive | 27 |
higher risk | 27 |
population density | 27 |
exosomes derived | 27 |
high resolution | 27 |
multiple myeloma | 27 |
pcr reaction | 27 |
clinical significance | 27 |
circulating evs | 27 |
prevalence rate | 27 |
water treatment | 27 |
solid phase | 27 |
target dna | 27 |
blood system | 27 |
flow cytometer | 27 |
air embolism | 27 |
molecular weight | 27 |
direct antiglobulin | 27 |
mean ae | 27 |
extracellular matrix | 27 |
quantified using | 27 |
indirect antiglobulin | 27 |
nasal cavity | 27 |
hbv dna | 27 |
incubation period | 26 |
throughput sequencing | 26 |
units transfused | 26 |
transfusion recipients | 26 |
hospital transfusion | 26 |
per day | 26 |
immune cells | 26 |
human serum | 26 |
protein markers | 26 |
one week | 26 |
considered significant | 26 |
cross sections | 26 |
influenza viruses | 26 |
monoclonal anti | 26 |
disease surveillance | 26 |
physical activity | 26 |
samples showed | 26 |
infected individuals | 26 |
normal dogs | 26 |
old female | 26 |
cell transfusion | 26 |
cell carcinoma | 26 |
coronary artery | 26 |
water samples | 26 |
inventory management | 26 |
confidence interval | 26 |
phylogenetic analysis | 26 |
rheumatoid arthritis | 26 |
days post | 26 |
negative blood | 26 |
weight loss | 26 |
human health | 26 |
respiratory infections | 26 |
nasopharynx samples | 26 |
transfusion therapy | 26 |
endothelial cell | 26 |
findings suggest | 26 |
spectra optia | 26 |
fatty acid | 26 |
master mix | 26 |
developing countries | 26 |
specific antibodies | 26 |
dengue virus | 26 |
blot analysis | 26 |
clinical setting | 26 |
also observed | 26 |
sample types | 26 |
affected dogs | 26 |
transfusion practices | 26 |
significantly associated | 26 |
complete blood | 25 |
bacterial growth | 25 |
infected cells | 25 |
blood alcohol | 25 |
blood count | 25 |
tertiary care | 25 |
coronavirus disease | 25 |
disease control | 25 |
column agglutination | 25 |
clinical outcomes | 25 |
wild type | 25 |
environmental dna | 25 |
platelet transfusions | 25 |
will help | 25 |
confocal microscopy | 25 |
cats without | 25 |
hiv urine | 25 |
compared using | 25 |
iron depletion | 25 |
results demonstrate | 25 |
nasopharyngeal flora | 25 |
free dna | 25 |
based assays | 25 |
bowel disease | 25 |
viral genome | 25 |
using different | 25 |
hla antibodies | 25 |
compatible blood | 25 |
vast majority | 25 |
described previously | 25 |
obtained using | 25 |
information regarding | 25 |
platelet content | 25 |
four samples | 25 |
inflammatory response | 25 |
detection methods | 25 |
class i | 25 |
syndrome coronavirus | 25 |
much higher | 25 |
bacillus anthracis | 25 |
may affect | 25 |
donor center | 24 |
blood screening | 24 |
previously shown | 24 |
blood grouping | 24 |
may serve | 24 |
cells treated | 24 |
supplementary table | 24 |
two years | 24 |
sample volume | 24 |
igg antibody | 24 |
mycobacterium tuberculosis | 24 |
detection system | 24 |
gastrointestinal disease | 24 |
serological testing | 24 |
immunosorbent assay | 24 |
human blood | 24 |
blood vessel | 24 |
screening test | 24 |
hiv infection | 24 |
inflammatory cytokines | 24 |
correlation coefficient | 24 |
large scale | 24 |
blood specimens | 24 |
infected dogs | 24 |
nonfarmworker families | 24 |
currently available | 24 |
cell type | 24 |
pulmonary edema | 24 |
canine astrovirus | 24 |
significant decrease | 24 |
six months | 24 |
general anesthesia | 24 |
membrane vesicles | 24 |
cdna synthesis | 24 |
ev numbers | 24 |
cell migration | 24 |
per unit | 24 |
blood culture | 24 |
diagnostic laboratory | 24 |
metagenomic analysis | 24 |
flow cell | 24 |
small dogs | 24 |
blood glucose | 24 |
within minutes | 23 |
skeletal muscle | 23 |
light scattering | 23 |
viral particles | 23 |
studies will | 23 |
ventricular septal | 23 |
critically ill | 23 |
data collection | 23 |
ambient air | 23 |
fatty acids | 23 |
two weeks | 23 |
significant reduction | 23 |
pathogen detection | 23 |
abo typing | 23 |
thermal cycling | 23 |
clinical settings | 23 |
tissue culture | 23 |
amino acids | 23 |
consensus sequence | 23 |
congestive heart | 23 |
carbon monoxide | 23 |
fold change | 23 |
also may | 23 |
care unit | 23 |
exosomes isolated | 23 |
hemoglobin levels | 23 |
serum ferritin | 23 |
microbial load | 23 |
large numbers | 23 |
management system | 23 |
reactive samples | 23 |
stranded dna | 23 |
particles ml | 23 |
gel electrophoresis | 23 |
will provide | 23 |
confirmed positive | 23 |
platelet yield | 23 |
microarray technology | 23 |
creative commons | 23 |
cell viability | 23 |
acute diarrhoea | 23 |
buffered saline | 23 |
arachidonic acid | 23 |
done using | 23 |
durum wheat | 23 |
donor deferral | 23 |
prepared using | 23 |
linked immunosorbent | 23 |
thrombotic thrombocytopenic | 23 |
exact test | 23 |
long term | 23 |
rhd beadchip | 23 |
poorly understood | 23 |
storage time | 23 |
samples obtained | 23 |
may represent | 23 |
method using | 23 |
mononuclear cells | 23 |
genetic analysis | 23 |
dna polymerase | 23 |
handheld optical | 23 |
study demonstrates | 23 |
square test | 23 |
surgical mask | 23 |
mesenchymal stromal | 23 |
transfusion associated | 23 |
blood plasma | 23 |
dependent manner | 22 |
rhd typing | 22 |
large volume | 22 |
colorectal cancer | 22 |
serial dilutions | 22 |
may require | 22 |
ev protein | 22 |
gold nanoparticles | 22 |
way anova | 22 |
evs may | 22 |
protein concentration | 22 |
molecular mechanisms | 22 |
genotyping results | 22 |
authors declare | 22 |
manual tube | 22 |
single ev | 22 |
two days | 22 |
left atrial | 22 |
samples containing | 22 |
ev preparations | 22 |
derived ev | 22 |
nucleotide identity | 22 |
samples per | 22 |
hb content | 22 |
cobe spectra | 22 |
adipose tissue | 22 |
marrow transplantation | 22 |
high incidence | 22 |
laboratory tests | 22 |
different blood | 22 |
posted june | 22 |
retrospective review | 22 |
investigate whether | 22 |
national institute | 22 |
trauma patients | 22 |
rights reserved | 22 |
disease severity | 22 |
donated blood | 22 |
risk assessment | 22 |
serum tt | 22 |
pool testing | 22 |
bovine serum | 22 |
patient population | 22 |
platelet activation | 22 |
outer membrane | 22 |
specimen collection | 22 |
null hypothesis | 22 |
iron stores | 22 |
tumour growth | 22 |
based tests | 22 |
study shows | 22 |
bleeding patients | 22 |
immune responses | 22 |
light microscopy | 22 |
predictive value | 22 |
image processing | 22 |
cell cultures | 22 |
surface water | 22 |
mayo clinic | 22 |
nasal swabs | 22 |
cardiovascular disease | 22 |
water source | 22 |
faecium ncimb | 22 |
inflammatory bowel | 22 |
collected using | 22 |
group testing | 22 |
rhd weak | 22 |
buffy coats | 22 |
cells using | 21 |
allowed without | 21 |
based amplification | 21 |
treated rbcs | 21 |
infected patients | 21 |
many cases | 21 |
based assay | 21 |
antibody titers | 21 |
protein levels | 21 |
flow rate | 21 |
serologic testing | 21 |
quantitative pcr | 21 |
hev rna | 21 |
significant changes | 21 |
quality improvement | 21 |
data demonstrate | 21 |
serum cobalamin | 21 |
lupus erythematosus | 21 |
respiratory viral | 21 |
pooled sample | 21 |
group systems | 21 |
respiratory virus | 21 |
repeated measures | 21 |
prevalence rates | 21 |
evs showed | 21 |
using pcr | 21 |
oral cavity | 21 |
dried blood | 21 |
blood flow | 21 |
thrombocytopenic purpura | 21 |
ev surface | 21 |
broiler chickens | 21 |
pulmonary artery | 21 |
blood ordering | 21 |
ae sd | 21 |
pulse sensing | 21 |
residual risk | 21 |
two dogs | 21 |
patient outcomes | 21 |
better understanding | 21 |
small rnas | 21 |
electrochemical detection | 21 |
platelet concentrate | 21 |
medical research | 21 |
without permission | 21 |
biological material | 21 |
bovine respiratory | 21 |
contaminated water | 21 |
time required | 21 |
hazara virus | 21 |
ev populations | 21 |
patients compared | 21 |
reference range | 21 |
class ii | 21 |
renal disease | 21 |
antibody detection | 21 |
may contribute | 21 |
diagnostic tool | 21 |
ev proteins | 21 |
detection sensitivity | 21 |
filter paper | 21 |
within min | 21 |
therapeutic potential | 21 |
table i | 21 |
sequence reads | 21 |
follow procedures | 21 |
low ferritin | 21 |
host disease | 21 |
lateral recumbency | 21 |
laboratory results | 21 |
detection rate | 21 |
reuse allowed | 21 |
study using | 20 |
cytologic examination | 20 |
patients treated | 20 |
samples may | 20 |
published data | 20 |
control horses | 20 |
rhd positive | 20 |
deferral rates | 20 |
microfluidic device | 20 |
needle aspiration | 20 |
university school | 20 |
storage lesion | 20 |
clostridium difficile | 20 |
cells ml | 20 |
renal function | 20 |
european union | 20 |
detection limit | 20 |
affected samples | 20 |
group antigen | 20 |
sequence analysis | 20 |
donor recruitment | 20 |
readily available | 20 |
cellular uptake | 20 |
human metapneumovirus | 20 |
clinical applications | 20 |
relatively low | 20 |
may play | 20 |
rich plasma | 20 |
closed system | 20 |
exosome secretion | 20 |
hla class | 20 |
skin lesions | 20 |
large evs | 20 |
rhd variant | 20 |
expression level | 20 |
microfluidic devices | 20 |
using blastn | 20 |
first study | 20 |
clinical studies | 20 |
disease progression | 20 |
reactive protein | 20 |
pulmonary fibrosis | 20 |
vena cava | 20 |
cardiac surgery | 20 |
resistive pulse | 20 |
recent advances | 20 |
four different | 20 |
cross blood | 20 |
new automated | 20 |
glass slide | 20 |
additional studies | 20 |
posted april | 20 |
direct rna | 20 |
cell antigens | 20 |
false negatives | 20 |
chronic kidney | 20 |
chlamydia trachomatis | 20 |
hemoglobin level | 20 |
blood spots | 20 |
north carolina | 20 |
extracted using | 20 |
ovarian cancer | 20 |
laboratory testing | 20 |
cell lymphoma | 20 |
febrile illness | 20 |
cervical cancer | 20 |
cd deficiency | 20 |
great potential | 20 |
tumour progression | 20 |
zikv rna | 20 |
also showed | 20 |
times higher | 20 |
canadian blood | 20 |
dry hcqs | 20 |
batrachochytrium salamandrivorans | 20 |
cell concentrates | 20 |
viral species | 20 |
health issues | 20 |
north america | 20 |
dna microarrays | 20 |
beckman coulter | 20 |
low levels | 20 |
recreational water | 20 |
sample vf | 20 |
acid sequence | 20 |
systemic lupus | 19 |
saharan africa | 19 |
analytical sensitivity | 19 |
normally distributed | 19 |
urine testing | 19 |
contact time | 19 |
well known | 19 |
insulin resistance | 19 |
donor health | 19 |
amplicon sequencing | 19 |
lysis buffer | 19 |
hcv rna | 19 |
likely due | 19 |
significantly improved | 19 |
selection criteria | 19 |
hiv positive | 19 |
lung injury | 19 |
post transfusion | 19 |
bacterial cells | 19 |
table shows | 19 |
mammalian viruses | 19 |
io catheter | 19 |
hb level | 19 |
potential biomarkers | 19 |
developed countries | 19 |
will also | 19 |
teaching hospital | 19 |
interstitial pneumonia | 19 |
among different | 19 |
differential diagnosis | 19 |
patient identification | 19 |
taken together | 19 |
one dog | 19 |
catheter insertion | 19 |
different levels | 19 |
surveillance system | 19 |
common cause | 19 |
sectional study | 19 |
research institute | 19 |
national institutes | 19 |
also significantly | 19 |
endemic areas | 19 |
cycle threshold | 19 |
high specificity | 19 |
better understand | 19 |
repeat testing | 19 |
expression analysis | 19 |
mirna expression | 19 |
laboratory data | 19 |
final concentration | 19 |
negative pressure | 19 |
emergency department | 19 |
cd evs | 19 |
indicator organisms | 19 |
regular blood | 19 |
mrna expression | 19 |
ev detection | 19 |
ev secretion | 19 |
new donors | 19 |
minion barcodes | 19 |
low cost | 19 |
routinely used | 19 |
healthy horses | 19 |
cell function | 19 |
hla typing | 19 |
key role | 19 |
amplification reaction | 19 |
large amounts | 19 |
made using | 19 |
potential role | 19 |
conducted using | 19 |
clinical sample | 19 |
years ago | 19 |
preliminary results | 19 |
reactive results | 19 |
apheresis donors | 19 |
hospital blood | 19 |
will enable | 19 |
cancer progression | 19 |
statistical analyses | 19 |
limited settings | 19 |
clinical respiratory | 19 |
average number | 19 |
axenic culture | 19 |
epithelial cell | 19 |
fold higher | 19 |
extraction methods | 19 |
different ev | 19 |
platelet inventory | 19 |
markers cd | 19 |
amotosalen uva | 19 |
two cases | 19 |
automated blood | 19 |
positive result | 19 |
right ventricular | 19 |
sensitive detection | 18 |
storage conditions | 18 |
healthy volunteers | 18 |
significant number | 18 |
routine use | 18 |
pretransfusion testing | 18 |
transfusion related | 18 |
magnetic resonance | 18 |
antibody positive | 18 |
molecular analysis | 18 |
rbc unit | 18 |
cell count | 18 |
probiotic bacterium | 18 |
dtt treatment | 18 |
health dynamics | 18 |
hydration water | 18 |
pooled platelet | 18 |
free water | 18 |
reagent red | 18 |
total evs | 18 |
differential expression | 18 |
two methods | 18 |
health system | 18 |
computed tomography | 18 |
bacterial pathogens | 18 |
several times | 18 |
positive test | 18 |
genome coverage | 18 |
cell death | 18 |
ev size | 18 |
virus sequences | 18 |
com scientificreports | 18 |
nasal swab | 18 |
based method | 18 |
architect i | 18 |
apheresis procedures | 18 |
respiratory panel | 18 |
white matter | 18 |
supervised learning | 18 |
sample type | 18 |
using standard | 18 |
without compromising | 18 |
molecular methods | 18 |
avian influenza | 18 |
cd cell | 18 |
ev biogenesis | 18 |
raman spectroscopy | 18 |
total blood | 18 |
reads per | 18 |
associated proteins | 18 |
study included | 18 |
genetic material | 18 |
next step | 18 |
histologic sections | 18 |
microbiologic study | 18 |
healthy adult | 18 |
complex samples | 18 |
state university | 18 |
antibody titer | 18 |
tube testing | 18 |
institutional review | 18 |
oxford nanopore | 18 |
temporal mental | 18 |
plasma transfusion | 18 |
healthy cats | 18 |
infectious peritonitis | 18 |
current methods | 18 |
spike protein | 18 |
i ii | 18 |
pathogenic viruses | 18 |
data indicate | 18 |
assay time | 18 |
screening tool | 18 |
plasmodium falciparum | 18 |
per patient | 18 |
enzyme activity | 18 |
rhd exon | 18 |
purified evs | 18 |
viral nucleic | 18 |
study aims | 18 |
viral titers | 18 |
hcqs sample | 18 |
tumour cell | 18 |
different methods | 18 |
aortic arch | 18 |
serum concentrations | 18 |
previous study | 18 |
several studies | 18 |
bacterial infections | 18 |
competing interests | 18 |
hematology analyzer | 18 |
antibiotic resistance | 18 |
sample pools | 18 |
msc evs | 18 |
hiv ag | 18 |
rhd variants | 18 |
significant antibodies | 18 |
internal control | 18 |
much lower | 18 |
culture results | 18 |
low level | 18 |
ag ab | 18 |
previously published | 18 |
positive dat | 18 |
feline infectious | 18 |
many different | 18 |
hyperthyroid cats | 18 |
data showed | 18 |
respiratory infection | 18 |
antibody tests | 18 |
drug administration | 18 |
cell wall | 17 |
molecular basis | 17 |
fluorescence microscopy | 17 |
enteric disease | 17 |
platelet additive | 17 |
transport media | 17 |
copies per | 17 |
positive antibody | 17 |
plasma concentrations | 17 |
blood smear | 17 |
delayed hemolytic | 17 |
review board | 17 |
controlled trial | 17 |
triple negative | 17 |
sequencing using | 17 |
genetic diversity | 17 |
wt mice | 17 |
data set | 17 |
sample matrix | 17 |
dendritic cells | 17 |
ev uptake | 17 |
study evaluated | 17 |
early diagnosis | 17 |
i sr | 17 |
direct pcr | 17 |
rejuvenation solution | 17 |
spiked samples | 17 |
ev samples | 17 |
size range | 17 |
three years | 17 |
endotracheal tube | 17 |
ordered hydrated | 17 |
test samples | 17 |
studies using | 17 |
cmv igg | 17 |
may suggest | 17 |
healthy subjects | 17 |
viral transport | 17 |
pcr tests | 17 |
clinical relevance | 17 |
higher levels | 17 |
consecutive days | 17 |
adverse outcomes | 17 |
cell evs | 17 |
crucial role | 17 |
hospital background | 17 |
ae ml | 17 |
detection using | 17 |
one unit | 17 |
antigen tests | 17 |
samples compared | 17 |
hemolytic uremic | 17 |
evs secreted | 17 |
forming units | 17 |
data obtained | 17 |
ml min | 17 |
water molecules | 17 |
irradiated blood | 17 |
three times | 17 |
increased levels | 17 |
rh blood | 17 |
similar results | 17 |
clinical diagnostic | 17 |
study group | 17 |
throat swabs | 17 |
electron microscopic | 17 |
health status | 17 |
virus type | 17 |
tract disease | 17 |
oral administration | 17 |
one another | 17 |
blood smears | 17 |
buffered formalin | 17 |
respiratory diseases | 17 |
herpes simplex | 17 |
pathway analysis | 17 |
time consuming | 17 |
screening tests | 17 |
plasma using | 17 |
low prevalence | 17 |
small sample | 17 |
using rt | 17 |
iron overload | 17 |
collect samples | 17 |
pcr primers | 17 |
characterized using | 17 |
direct naats | 17 |
cell cycle | 17 |
target species | 17 |
gradient ultracentrifugation | 17 |
low sensitivity | 17 |
tangential flow | 17 |
signalling pathways | 17 |
flow filtration | 17 |
sampling methods | 17 |
allogeneic blood | 17 |
culture conditions | 17 |
stored rbcs | 17 |
group received | 17 |
quality management | 17 |
novel viruses | 17 |
rna samples | 17 |
simultaneous detection | 17 |
cell activation | 17 |
prosthetic repair | 17 |
brain barrier | 17 |
middle east | 17 |
wbc count | 17 |
also identified | 17 |
transfusion testing | 17 |
new england | 17 |
different cell | 17 |
three months | 17 |
recent study | 17 |
leucocyte depleted | 17 |
nucleotide polymorphisms | 17 |
donor blood | 17 |
anaplasma phagocytophilum | 17 |
immunoassay cassette | 17 |
pig farmer | 17 |
may indicate | 17 |
guano samples | 17 |
immune cell | 17 |
transfusion center | 17 |
condition score | 17 |
leading cause | 17 |
antigen typing | 17 |
antibody screens | 17 |
blood banking | 17 |
amplification process | 17 |
blood gas | 17 |
replacement therapy | 17 |
serum creatinine | 17 |
cold storage | 17 |
positive donors | 16 |
rare blood | 16 |
poor prognosis | 16 |
observational study | 16 |
antibody avidity | 16 |
six healthy | 16 |
gene deletion | 16 |
blood derived | 16 |
factor viii | 16 |
detection method | 16 |
prepare roentgenograms | 16 |
alkaline phosphatase | 16 |
survival time | 16 |
purified using | 16 |
wide variety | 16 |
binding sites | 16 |
component analysis | 16 |
nat screening | 16 |
clinical disease | 16 |
rhd diiia | 16 |
fresenius kabi | 16 |
genome copies | 16 |
pluripotent stem | 16 |
sequencing approach | 16 |
waterborne disease | 16 |
wore masks | 16 |
nasal discharge | 16 |
supplementary material | 16 |
gel cards | 16 |
one hour | 16 |
rna extracted | 16 |
high expression | 16 |
cell derived | 16 |
blood agar | 16 |
product utilization | 16 |
negative breast | 16 |
exosome isolation | 16 |
least two | 16 |
evs using | 16 |
mott cross | 16 |
will allow | 16 |
rbc alloantibodies | 16 |
record weight | 16 |
cystic fibrosis | 16 |
using high | 16 |
different concentrations | 16 |
therapeutic effect | 16 |
enteric viruses | 16 |
biopsy samples | 16 |
synovial fluid | 16 |
rbc alloimmunization | 16 |
evs containing | 16 |
days prior | 16 |
heavy metal | 16 |
adverse event | 16 |
leucine codon | 16 |
allele frequencies | 16 |
iron status | 16 |
rna molecules | 16 |
concept study | 16 |
volume reduction | 16 |
regenerative medicine | 16 |
test kits | 16 |
surface antigen | 16 |
rbc exchange | 16 |
affected horses | 16 |
virus infections | 16 |
samples contained | 16 |
supply chain | 16 |
lung tissue | 16 |
atomic force | 16 |
breast milk | 16 |
transfusion support | 16 |
dust period | 16 |
tested negative | 16 |
predicted phenotype | 16 |
additional file | 16 |
circulating extracellular | 16 |
new method | 16 |
processing time | 16 |
significant correlation | 16 |
mass index | 16 |
pancreatic cancer | 16 |
san diego | 16 |
marrow aspiration | 16 |
small amounts | 16 |
severe disease | 16 |
improve patient | 16 |
close contact | 16 |
units per | 16 |
using differential | 16 |
nonfarmworker sample | 16 |
clinical presentation | 16 |
short time | 16 |
income countries | 16 |
rbcs stored | 16 |
commonly found | 16 |
microarray data | 16 |
young children | 16 |
amr genes | 16 |
shar peis | 16 |
clinical outcome | 16 |
hbv infection | 16 |
current state | 16 |
uremic syndrome | 16 |
respiratory specimens | 16 |
myocardial infarction | 16 |
viral targets | 16 |
human platelet | 16 |
standard operating | 16 |
rhd alleles | 16 |
contigs assigned | 16 |
blood bags | 16 |
expression patterns | 16 |
series classification | 16 |
gi disease | 16 |
clinical use | 16 |
rapid diagnostic | 16 |
filtration efficiency | 16 |
incubation time | 16 |
feline coronavirus | 16 |
different stages | 16 |
secondary electron | 16 |
national university | 16 |
also determined | 16 |
viral target | 16 |
log ml | 16 |
donor safety | 16 |
mean number | 16 |
testing using | 16 |
donor plasma | 16 |
pathogen reduced | 16 |
much less | 16 |
assess whether | 16 |
controlled trials | 16 |
feature learning | 16 |
well suited | 15 |
time intervals | 15 |
chronic inflammation | 15 |
mini kit | 15 |
dna sequences | 15 |
pcr master | 15 |
jugular vein | 15 |
largely unknown | 15 |
dynamic light | 15 |
coronary arteries | 15 |
experimental data | 15 |
two species | 15 |
sample volumes | 15 |
identified using | 15 |
spinal canal | 15 |
quantitative real | 15 |
liquid nitrogen | 15 |
generated using | 15 |
farmworker sample | 15 |
ev research | 15 |
pcr test | 15 |
sequencing technologies | 15 |
care diagnostics | 15 |
causative agent | 15 |
lavage fluid | 15 |
faecal viromes | 15 |
glass slides | 15 |
must also | 15 |
clinically important | 15 |
blood mononuclear | 15 |
many countries | 15 |
west africa | 15 |
healthcare workers | 15 |
sample sizes | 15 |
seven days | 15 |
predicted locations | 15 |
saliva samples | 15 |
lung disease | 15 |
potential risk | 15 |
laboratory information | 15 |
pcr results | 15 |
cd monoclonal | 15 |
old male | 15 |
activation energy | 15 |
based approach | 15 |
increased expression | 15 |
human pathogens | 15 |
ev quantification | 15 |
may vary | 15 |
relative abundances | 15 |
higher number | 15 |
wastewater workers | 15 |
detection range | 15 |
positive patients | 15 |
nucleotide polymorphism | 15 |
routine diagnostic | 15 |
ms analysis | 15 |
abdominal cavity | 15 |
foreign body | 15 |
pcr reactions | 15 |
small ev | 15 |
rapid identification | 15 |
blood stem | 15 |
gradient centrifugation | 15 |
timely manner | 15 |
case definition | 15 |
rbc products | 15 |
blood processing | 15 |
standard tube | 15 |
water bath | 15 |
data sets | 15 |
biological activity | 15 |
type unspecified | 15 |
limited number | 15 |
positive correlation | 15 |
thrombus formation | 15 |
novo assembly | 15 |
id rhd | 15 |
carlo simulation | 15 |
unaffected samples | 15 |
force microscopy | 15 |
random hexamers | 15 |
world samples | 15 |
autoimmune hemolytic | 15 |
fluorescence detection | 15 |
ev treatment | 15 |
pcr testing | 15 |
national cancer | 15 |
vivo studies | 15 |
operatory surfaces | 15 |
days later | 15 |
based blood | 15 |
viral diversity | 15 |
donor return | 15 |
per cell | 15 |
normal rhd | 15 |
saline solution | 15 |
bacterial evs | 15 |
cell counts | 15 |
rhd xt | 15 |
first two | 15 |
surface plasmon | 15 |
clinical evaluation | 15 |
donor retention | 15 |
human urine | 15 |
intranasal administration | 15 |
using either | 15 |
pulmonary valve | 15 |
dna analysis | 15 |
literature review | 15 |
autopsy procedures | 15 |
two patients | 15 |
well established | 15 |
probe sets | 15 |
response rate | 15 |
human cd | 15 |
fluorescent dyes | 15 |
clinical impact | 15 |
full genome | 15 |
significant effect | 15 |
water sources | 15 |
situ hybridization | 15 |
evidence based | 15 |
two types | 15 |
brain stem | 15 |
imaging flow | 15 |
hla antibody | 15 |
plant viruses | 15 |
amplification assay | 15 |
see note | 15 |
platelet antigens | 15 |
hb deferral | 15 |
type diabetes | 15 |
tpe procedures | 15 |
displacement amplification | 15 |
low dose | 15 |
evs produced | 15 |
high concentration | 15 |
gene sequencing | 15 |
ev concentration | 15 |
data samples | 15 |
small cell | 15 |
centrifugal microfluidic | 15 |
human coronavirus | 15 |
different isolation | 15 |
patients requiring | 15 |
south africa | 15 |
viral proteins | 15 |
dna damage | 15 |
sudden death | 15 |
signalling pathway | 15 |
miseq sequencing | 15 |
incubation periods | 15 |
slightly lower | 15 |
transfusion guidelines | 15 |
data points | 15 |
methyl groups | 15 |
microfluidic systems | 15 |
test sample | 15 |
well plates | 15 |
past years | 15 |
adult cats | 15 |
progenitor cell | 15 |
canine parvovirus | 15 |
correlation among | 15 |
biological fluids | 15 |
ferritin testing | 15 |
pcr using | 15 |
new approach | 15 |
frequently used | 15 |
respiratory distress | 15 |
slightly higher | 15 |
specific markers | 15 |
mast cells | 15 |
cd exo | 15 |
case study | 15 |
antibody test | 15 |
neg rbc | 14 |
day post | 14 |
free plasma | 14 |
showed significant | 14 |
using spss | 14 |
may reflect | 14 |
nucleotide sequences | 14 |
mitral valves | 14 |
two units | 14 |
cell collection | 14 |
newly developed | 14 |
cell antibodies | 14 |
single donor | 14 |
routine blood | 14 |
surface protein | 14 |
rna virus | 14 |
also detected | 14 |
multiplex real | 14 |
replacement fluid | 14 |
normal saline | 14 |
dna sequence | 14 |
new blood | 14 |
liver biopsy | 14 |
bacterial community | 14 |
single unit | 14 |
human brain | 14 |
chloroquine phosphate | 14 |
ionized calcium | 14 |
cancer institute | 14 |
dna microarray | 14 |
virus genome | 14 |
platelet cd | 14 |
clinical diagnostics | 14 |
reaction mixture | 14 |
sampling results | 14 |
typing results | 14 |
fda approved | 14 |
cardiac disease | 14 |
tube methods | 14 |
comparator assay | 14 |
regression models | 14 |
acute kidney | 14 |
african american | 14 |
relatively small | 14 |
cell antibody | 14 |
medical care | 14 |
emergency release | 14 |
fungal infections | 14 |
results indicated | 14 |
standard methods | 14 |
iv iron | 14 |
htlv i | 14 |
previously identified | 14 |
positive controls | 14 |
control sample | 14 |
antigen negative | 14 |
decision making | 14 |
hepatocellular carcinoma | 14 |
obese dogs | 14 |
procedures performed | 14 |
proteomic profiling | 14 |
hong kong | 14 |
patient received | 14 |
healthy individuals | 14 |
genetic variants | 14 |
protective equipment | 14 |
acquired immunodeficiency | 14 |
nat yield | 14 |
blood testing | 14 |
stored platelets | 14 |
component preparation | 14 |
also demonstrated | 14 |
clinical cases | 14 |
sample pretreatment | 14 |
deferral rate | 14 |
abo genotyping | 14 |
gel card | 14 |
phosphate buffered | 14 |
control study | 14 |
connective tissue | 14 |
plt count | 14 |
lower concentrations | 14 |
useful tool | 14 |
respiratory illness | 14 |
drug delivery | 14 |
allogeneic donors | 14 |
ml syringe | 14 |
data suggests | 14 |
environmental conditions | 14 |
away time | 14 |
donor program | 14 |
thawed plasma | 14 |
volume processed | 14 |
rna sequences | 14 |
storage duration | 14 |
well plate | 14 |
western blots | 14 |
month deferral | 14 |
labelled evs | 14 |
group ab | 14 |
reads aligning | 14 |
microarray analysis | 14 |
data management | 14 |
different regions | 14 |
chemical composition | 14 |
laser scanning | 14 |
brain tissue | 14 |
recently demonstrated | 14 |
rrna gene | 14 |
regular donors | 14 |
sample introduction | 14 |
comparative analysis | 14 |
gis gps | 14 |
taxonomic profiles | 14 |
single sample | 14 |
transfusion strategies | 14 |
west nile | 14 |
target sequence | 14 |
venous blood | 14 |
emergency blood | 14 |
mycoplasma spp | 14 |
rna library | 14 |
prevalence antigen | 14 |
risk management | 14 |
copy numbers | 14 |
medical history | 14 |
strand displacement | 14 |
iron metabolism | 14 |
dg gel | 14 |
often used | 14 |
assay kit | 14 |
molecular typing | 14 |
right ventricle | 14 |
one case | 14 |
quantitative analysis | 14 |
gauge needle | 14 |
statistical difference | 14 |
study provides | 14 |
septic transfusion | 14 |
negative rbcs | 14 |
training period | 14 |
circulatory overload | 14 |
two distinct | 14 |
study showed | 14 |
cell adhesion | 14 |
gram stain | 14 |
amniotic fluid | 14 |
integrated microfluidic | 14 |
image analysis | 14 |
available data | 14 |
incidence rate | 14 |
significant impact | 14 |
study suggests | 14 |
method used | 14 |
flow strips | 14 |
positive rate | 14 |
evaluate whether | 14 |
split rate | 14 |
one month | 14 |
united kingdom | 14 |
bone metastasis | 14 |
major role | 14 |
sample testing | 14 |
adult patients | 14 |
recurrent group | 14 |
sampling method | 14 |
typhoid fever | 14 |
none required | 14 |
pcr method | 14 |
ev yield | 14 |
early stage | 14 |
stranded rna | 14 |
sterile saline | 14 |
biothreat agents | 14 |
rbc antigens | 14 |
highly variable | 14 |
cognitive impairment | 14 |
based transfusion | 14 |
irradiated rbcs | 14 |
pcr positive | 14 |
colony forming | 14 |
microfluidic platform | 14 |
treatment groups | 14 |
opportunistic pathogens | 14 |
pivotal role | 14 |
clinical laboratory | 14 |
training set | 14 |
clinical diagnosis | 14 |
donating blood | 14 |
microbial communities | 14 |
mirna cargo | 14 |
genetic testing | 14 |
water bodies | 14 |
blood systems | 14 |
cost savings | 14 |
phase contrast | 14 |
study demonstrated | 14 |
amplification method | 14 |
human medicine | 14 |
take place | 14 |
cells expressing | 14 |
sample collected | 14 |
differential abundance | 14 |
different sources | 14 |
igg antibodies | 13 |
casein micelles | 13 |
chronically transfused | 13 |
database using | 13 |
low number | 13 |
among patients | 13 |
studies showed | 13 |
caudal cranial | 13 |
methionine codon | 13 |
poc devices | 13 |
supplementary file | 13 |
stool sample | 13 |
critical role | 13 |
independently associated | 13 |
see disease | 13 |
kernel density | 13 |
clinical features | 13 |
mean hb | 13 |
overall survival | 13 |
magnetic force | 13 |
molecular cargo | 13 |
cells kg | 13 |
ev released | 13 |
compatibility testing | 13 |
classified using | 13 |
lactate levels | 13 |
acid test | 13 |
fluorescently labelled | 13 |
known viruses | 13 |
strongly associated | 13 |
maternal plasma | 13 |
help us | 13 |
using nanoparticle | 13 |
based dna | 13 |
genetic variation | 13 |
highly expressed | 13 |
biodefense applications | 13 |
copy number | 13 |
shotgun sequencing | 13 |
primary care | 13 |
healthcare system | 13 |
panel cells | 13 |
arterial blood | 13 |
another study | 13 |
total population | 13 |
specific gravity | 13 |
lower risk | 13 |
times per | 13 |
virus rna | 13 |
six sigma | 13 |
positive specimens | 13 |
blood supplier | 13 |
differentially abundant | 13 |
dna testing | 13 |
platelet recovery | 13 |
bioaerosol exposure | 13 |
genome amplification | 13 |
chronic disease | 13 |
ap activity | 13 |
random sampling | 13 |
antitrypsin deficiency | 13 |
abo discrepancy | 13 |
without agitation | 13 |
virus species | 13 |
evs compared | 13 |
simplex virus | 13 |
log reduction | 13 |
preoperative anemia | 13 |
fetal rhd | 13 |
cross match | 13 |
basic anomaly | 13 |
training samples | 13 |
i will | 13 |
strand synthesis | 13 |
personal protective | 13 |
quality indicators | 13 |
host cell | 13 |
patients without | 13 |
pregnant woman | 13 |
rural areas | 13 |
comparative study | 13 |
trauma center | 13 |
pooling strategy | 13 |
small size | 13 |
total volume | 13 |
left ventricle | 13 |
duke university | 13 |
complex biological | 13 |
rh antigens | 13 |
several different | 13 |
small intestine | 13 |
viral respiratory | 13 |
health effects | 13 |
drug abuse | 13 |
five different | 13 |
clinical course | 13 |
emergency use | 13 |
european countries | 13 |
aortic valve | 13 |
sequencing run | 13 |
less likely | 13 |
human respiratory | 13 |
short period | 13 |
normal horses | 13 |
provide information | 13 |
continuous flow | 13 |
autopsy room | 13 |
null phenotype | 13 |
significantly less | 13 |
biopsy punch | 13 |
high viral | 13 |
operating procedures | 13 |
small volumes | 13 |
principal component | 13 |
screening assays | 13 |
high cost | 13 |
great ape | 13 |
one group | 13 |
rna cargo | 13 |
acute pancreatitis | 13 |
vox sanguinis | 13 |
heme iron | 13 |
platelet components | 13 |
pulmonary arteries | 13 |
salmonella sp | 13 |
entire genome | 13 |
phase i | 13 |
second step | 13 |
detected using | 13 |
plasma concentration | 13 |
platelet concentration | 13 |
deep learning | 13 |
findings indicate | 13 |
factors associated | 13 |
cell processor | 13 |
water sample | 13 |
using anti | 13 |
laboratory staff | 13 |
isothermal nucleic | 13 |
human tissues | 13 |
cost effective | 13 |
low titer | 13 |
highest number | 13 |
transfusion laboratory | 13 |
donor unit | 13 |
rh phenotype | 13 |
vasovagal reactions | 13 |
dna viruses | 13 |
health agencies | 13 |
ko mice | 13 |
england biolabs | 13 |
proteomics data | 13 |
cranial fossa | 13 |
exosomal rna | 13 |
well tolerated | 13 |
adult dogs | 13 |
plastic bags | 13 |
alloimmunized patients | 13 |
see section | 13 |
expression data | 13 |
retrospective cohort | 13 |
active metabolite | 13 |
sevs isolated | 13 |
increased significantly | 13 |
south korea | 13 |
transfusion sample | 13 |
allergic reactions | 13 |
membrane proteins | 13 |
normal cats | 13 |
plasmon resonance | 13 |
cells may | 13 |
enzymatic amplification | 13 |
infective endocarditis | 13 |
biological processes | 13 |
first report | 13 |
cell populations | 13 |
standard lateral | 13 |
barr virus | 13 |
five years | 13 |
specific primer | 13 |
variant alleles | 13 |
clerical errors | 13 |
various types | 13 |
central blood | 13 |
around time | 13 |
disease patients | 13 |
animal models | 13 |
end reads | 13 |
donation frequency | 13 |
window predictions | 13 |
authors report | 13 |
among first | 13 |
unsupervised anomaly | 13 |
squamous cell | 13 |
negative donors | 13 |
molecular assays | 13 |
breed dogs | 13 |
amplification technologies | 13 |
adverse reaction | 13 |
platelet storage | 13 |
patient sample | 13 |
human papillomavirus | 13 |
transplant recipients | 13 |
neural networks | 13 |
methylene blue | 13 |
allowed us | 13 |
months post | 13 |
member states | 13 |
significant proportion | 13 |
clinical real | 13 |
heavy metals | 13 |
flow cells | 13 |
domestic animals | 13 |
clot formation | 13 |
study also | 13 |
like illness | 13 |
therapeutic target | 13 |
high degree | 13 |
prbc units | 13 |
diagnostic assay | 13 |
commons attribution | 13 |
remained stable | 13 |
genetic data | 13 |
adult foxes | 13 |
species identification | 13 |
enveloped viruses | 13 |
tof ms | 13 |
intestinal tract | 13 |
flow rates | 13 |
decreased significantly | 13 |
coagulation parameters | 13 |
raman spectra | 12 |
posted september | 12 |
current status | 12 |
term storage | 12 |
reverse type | 12 |
omeprazole treatment | 12 |
ab plasma | 12 |
great apes | 12 |
viral titer | 12 |
dissection techniques | 12 |
immature platelet | 12 |
east respiratory | 12 |
acute lung | 12 |
may therefore | 12 |
lymphocyte count | 12 |
airway obstruction | 12 |
tap water | 12 |
liver failure | 12 |
kidney injury | 12 |
photochemical treatment | 12 |
induced pluripotent | 12 |
echinococcus granulosus | 12 |
surface proteins | 12 |
associated protein | 12 |
transfusion transmission | 12 |
error rate | 12 |
one hand | 12 |
additional information | 12 |
using nanopore | 12 |
ribosomal rna | 12 |
based testing | 12 |
rna sequence | 12 |
titer results | 12 |
effective treatment | 12 |
remains unknown | 12 |
proteomics analysis | 12 |
polyethylene glycol | 12 |
swarm detection | 12 |
buccal swab | 12 |
pcr system | 12 |
plasma sample | 12 |
prospective cohort | 12 |
extraction method | 12 |
lifestyle factors | 12 |
also compared | 12 |
bacterial strains | 12 |
detection dogs | 12 |
also included | 12 |
immunohematology reference | 12 |
direct detection | 12 |
cytokine production | 12 |
biomedical research | 12 |
negative pregnant | 12 |
surgical procedures | 12 |
tranexamic acid | 12 |
environmental samples | 12 |
among data | 12 |
using commercial | 12 |
ferritin ng | 12 |
host immune | 12 |
vesicles introduction | 12 |
abo discrepancies | 12 |
exosomal markers | 12 |
muscle cells | 12 |
biomarker discovery | 12 |
minion sequencer | 12 |
rbc storage | 12 |
chagas disease | 12 |
ev characterization | 12 |
gene ontology | 12 |
ev concentrations | 12 |
blood establishments | 12 |
software version | 12 |
last decade | 12 |
oxygen species | 12 |
blood utilization | 12 |
related adverse | 12 |
high numbers | 12 |
liver transplantation | 12 |
crispr cas | 12 |
virus genomes | 12 |
soft tissues | 12 |
recursive method | 12 |
frequently detected | 12 |
true positive | 12 |
may become | 12 |
cd count | 12 |
san francisco | 12 |
based test | 12 |
following treatment | 12 |
rbc blood | 12 |
fever virus | 12 |
rh typing | 12 |
coding rnas | 12 |
enzyme immunoassay | 12 |
part ii | 12 |
total ev | 12 |
testing laboratory | 12 |
cell membrane | 12 |
data may | 12 |
plasma volume | 12 |
nosocomial transmission | 12 |
fluorescence intensity | 12 |
air sampling | 12 |
zeta potential | 12 |
also present | 12 |
tapestry pooling | 12 |
batrachochytrium dendrobatidis | 12 |
publicly available | 12 |
platelet loss | 12 |
test food | 12 |
cell growth | 12 |
urea nitrogen | 12 |
five days | 12 |
sample pool | 12 |
cytometry analysis | 12 |
large volumes | 12 |
results also | 12 |
muscular dystrophy | 12 |
post collection | 12 |
blood collected | 12 |
recombinase polymerase | 12 |
thermo scientific | 12 |
wastewater treatment | 12 |
samples will | 12 |
engineered evs | 12 |
first months | 12 |
without clinical | 12 |
incidence rates | 12 |
upper limit | 12 |
polymerase amplification | 12 |
dat positive | 12 |
much greater | 12 |
interquartile range | 12 |
diatom species | 12 |
cmnc protocol | 12 |
health problem | 12 |
abbott alinity | 12 |
pcr detection | 12 |
five samples | 12 |
risks associated | 12 |
viral peptides | 12 |
autoimmune diseases | 12 |
dogs received | 12 |
laboratory operations | 12 |
powerful tool | 12 |
detection module | 12 |
log iu | 12 |
transfused units | 12 |
treatment group | 12 |
nile virus | 12 |
big data | 12 |
reportable disease | 12 |
specific ev | 12 |
may influence | 12 |
adverse transfusion | 12 |
weeks later | 12 |
pneumatic tube | 12 |
second sample | 12 |
three methods | 12 |
allele frequency | 12 |
collection time | 12 |
diffuse alveolar | 12 |
dna using | 12 |
one positive | 12 |
higher sensitivity | 12 |
abdominal wall | 12 |
several days | 12 |
nitric oxide | 12 |
testing method | 12 |
exosomal mirna | 12 |
particle analysis | 12 |
three dogs | 12 |
alcohol concentration | 12 |
post thaw | 12 |
molecular changes | 12 |
high accuracy | 12 |
microscope slide | 12 |
widely available | 12 |
infected cats | 12 |
potential sources | 12 |
patient management | 12 |
tissue factor | 12 |
one day | 12 |
fluorescent signal | 12 |
management systems | 12 |
basecalling model | 12 |
patient plasma | 12 |
streptococcus pneumoniae | 12 |
accession numbers | 12 |
sequencing technology | 12 |
cell lung | 12 |
clinical manifestations | 12 |
care hospital | 12 |
estimated using | 12 |
body temperature | 12 |
parental cells | 12 |
one donor | 12 |
stomach tube | 12 |
ev analysis | 12 |
diagnostic procedures | 12 |
oral contamination | 12 |
murine macrophages | 12 |
randomly assigned | 12 |
cells showed | 12 |
immunodeficiency syndrome | 12 |
rna input | 12 |
alert level | 12 |
novel method | 12 |
broad range | 12 |
sewage samples | 12 |
clinical laboratories | 12 |
specific proteins | 12 |
alpha diversity | 12 |
ae standard | 12 |
quality assessment | 12 |
nanopore reads | 12 |
sputum samples | 12 |
serum sample | 12 |
direct amplification | 12 |
exosome markers | 12 |
health workers | 12 |
water supplies | 12 |
jaccard distance | 12 |
prediction error | 12 |
tests performed | 12 |
johns hopkins | 12 |
nt database | 12 |
rare donors | 12 |
virus circulation | 12 |
individual sample | 12 |
clinical information | 12 |
regression model | 12 |
community transmission | 12 |
phase ii | 12 |
owned dogs | 12 |
unlabeled data | 12 |
ductal artery | 12 |
research laboratory | 12 |
pcr based | 12 |
preparation methods | 12 |
rhd exons | 12 |
older adults | 12 |
neurodegenerative diseases | 12 |
nanopore metagenomic | 12 |
testing methods | 12 |
specific detection | 12 |
assay using | 12 |
central venous | 12 |
beneficial effects | 12 |
negative result | 12 |
clinical decision | 12 |
healthy control | 12 |
average cellularity | 12 |
immucor neo | 12 |
cell debris | 12 |
pd patients | 12 |
wb units | 12 |
give blood | 12 |
scattering cross | 12 |
dental operatory | 12 |
clinical utility | 12 |
working group | 12 |
recovery medium | 12 |
cobalamin deficiency | 12 |
reference sequences | 12 |
academic medical | 12 |
aplastic anemia | 12 |
hydrated sample | 12 |
mirasol prt | 12 |
carbon dioxide | 12 |